<p>对于 <strong>阿里巴巴健康信息技术有限公司</strong> (HKG:241) 来说，未来一段时间将会非常艰难，因其一周前发布了一些令人失望的年度业绩，这可能会显著影响市场对该股票的看法。阿里巴巴健康信息技术此次未能达到盈利预期，营收为 340 亿人民币，比分析师的预测低了 2.6%。法定每股收益（EPS）为 0.12 元人民币，也比预期低了 14%。盈利报告对投资者来说非常重要，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。我们认为读者会发现分析师最新的（法定）盈利报告后预测对明年很有趣。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711"/></p>
<p>SEHK:241 盈利与收入增长 2026 年 5 月 17 日</p>
<p>在最新业绩发布后，覆盖阿里巴巴健康信息技术的 14 位分析师现在预测 2027 年的营收为 390 亿人民币。如果实现，这将比过去 12 个月的营收增长 14%。每股收益预计将增长 9.9%，达到 0.13 元人民币。在这份报告发布之前，分析师们曾预测 2027 年的营收为 395 亿人民币，每股收益（EPS）为 0.17 元人民币。因此，在最新业绩发布后，情绪显然有所下降，新的每股收益预测也大幅下调。</p>
<p>查看我们对阿里巴巴健康信息技术的最新分析</p>
<p>共识目标价保持在 6.38 港元，分析师似乎认为他们下调的盈利预测不会在可预见的未来导致股价下跌。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对业务可能结果的不同看法。最乐观的阿里巴巴健康信息技术分析师的目标价为每股 12.43 港元，而最悲观的则为 3.60 港元。因此，在这种情况下，我们不应过于相信分析师的目标价，因为显然对该业务的表现存在广泛的不同看法。因此，基于共识目标价做出决策可能不是一个好主意，毕竟这只是这些广泛估计的平均值。</p>
<p>获取这些预测的更多背景信息的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。根据分析师的预测，到 2027 年底，营收预计将以 14% 的年化速度增长。这与过去五年的 14% 年增长率一致。与更广泛的行业相比，分析师的整体估计表明，行业营收预计将以 13% 的年增长率增长。显然，尽管阿里巴巴健康信息技术的营收增长预计将继续沿着当前轨迹发展，但其增长仅预计与行业本身持平。</p>
<h2>结论</h2>
<p>最大的问题是分析师下调了每股收益的预期，暗示阿里巴巴健康信息技术可能面临业务逆风。他们还重新确认了营收预期，预计公司将以与更广泛行业相同的速度增长。共识目标价保持在 6.38 港元，最新的估计不足以对他们的目标价产生影响。</p>
<p>基于这一思路，我们认为业务的长期前景远比明年的盈利更为重要。在 Simply Wall St，我们有阿里巴巴健康信息技术到 2029 年的完整分析师估计，您可以在我们的平台上免费查看。</p>
<p>您还可以查看我们对阿里巴巴健康信息技术董事会和首席执行官薪酬及经验的分析，以及公司内部人士是否在购买股票。</p>
<h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

阿里健康

汇添富中证医药卫生ETF

华夏医药ETF

易方达沪深300医药ETF

<p>阿里健康信息技术有限公司公布了令人失望的财报，每股收益（EPS）低于预期 14%，收入低于预期 2.6%。分析师已修订了他们的预测，预计到 2027 年收入将增加至 390 亿人民币，反映出 14% 的增长。尽管分析师的估计范围较广，但共识目标价仍维持在 6.38 港元。由于每股收益估计的下调引发了对未来业务挑战的担忧，而收入增长预计将与行业趋势保持一致</p>

<p>It's shaping up to be a tough period for <strong>Alibaba Health Information Technology Limited</strong> (HKG:241), which a week ago released some disappointing yearly results that could have a notable impact on how the market views the stock. Alibaba Health Information Technology missed earnings this time around, with CN¥34b revenue coming in 2.6% below what the analysts had modelled. Statutory earnings per share (EPS) of CN¥0.12 also fell short of expectations by 14%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.</p>
<div class="lb-trans"><p>对于 <strong>阿里巴巴健康信息技术有限公司</strong> (HKG:241) 来说，未来一段时间将会非常艰难，因其一周前发布了一些令人失望的年度业绩，这可能会显著影响市场对该股票的看法。阿里巴巴健康信息技术此次未能达到盈利预期，营收为 340 亿人民币，比分析师的预测低了 2.6%。法定每股收益（EPS）为 0.12 元人民币，也比预期低了 14%。盈利报告对投资者来说非常重要，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。我们认为读者会发现分析师最新的（法定）盈利报告后预测对明年很有趣。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711" alt="" original-src="https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711"/></p>
<p>SEHK:241 Earnings and Revenue Growth May 17th 2026</p>
<div class="lb-trans"><p>SEHK:241 盈利与收入增长 2026 年 5 月 17 日</p>
</div><p>After the latest results, the 14 analysts covering Alibaba Health Information Technology are now predicting revenues of CN¥39.0b in 2027. If met, this would reflect a notable 14% improvement in revenue compared to the last 12 months. Per-share earnings are expected to rise 9.9% to CN¥0.13. In the lead-up to this report, the analysts had been modelling revenues of CN¥39.5b and earnings per share (EPS) of CN¥0.17 in 2027. So there's definitely been a decline in sentiment after the latest results, noting the pretty serious reduction to new EPS forecasts.</p>
<div class="lb-trans"><p>在最新业绩发布后，覆盖阿里巴巴健康信息技术的 14 位分析师现在预测 2027 年的营收为 390 亿人民币。如果实现，这将比过去 12 个月的营收增长 14%。每股收益预计将增长 9.9%，达到 0.13 元人民币。在这份报告发布之前，分析师们曾预测 2027 年的营收为 395 亿人民币，每股收益（EPS）为 0.17 元人民币。因此，在最新业绩发布后，情绪显然有所下降，新的每股收益预测也大幅下调。</p>
</div><p>Check out our latest analysis for Alibaba Health Information Technology</p>
<div class="lb-trans"><p>查看我们对阿里巴巴健康信息技术的最新分析</p>
</div><p>The consensus price target held steady at HK$6.38, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Alibaba Health Information Technology analyst has a price target of HK$12.43 per share, while the most pessimistic values it at HK$3.60. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.</p>
<div class="lb-trans"><p>共识目标价保持在 6.38 港元，分析师似乎认为他们下调的盈利预测不会在可预见的未来导致股价下跌。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对业务可能结果的不同看法。最乐观的阿里巴巴健康信息技术分析师的目标价为每股 12.43 港元，而最悲观的则为 3.60 港元。因此，在这种情况下，我们不应过于相信分析师的目标价，因为显然对该业务的表现存在广泛的不同看法。因此，基于共识目标价做出决策可能不是一个好主意，毕竟这只是这些广泛估计的平均值。</p>
</div><p>One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 14% growth on an annualised basis. That is in line with its 14% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 13% annually. It's clear that while Alibaba Health Information Technology's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.</p>
<div class="lb-trans"><p>获取这些预测的更多背景信息的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。根据分析师的预测，到 2027 年底，营收预计将以 14% 的年化速度增长。这与过去五年的 14% 年增长率一致。与更广泛的行业相比，分析师的整体估计表明，行业营收预计将以 13% 的年增长率增长。显然，尽管阿里巴巴健康信息技术的营收增长预计将继续沿着当前轨迹发展，但其增长仅预计与行业本身持平。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Alibaba Health Information Technology. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at HK$6.38, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最大的问题是分析师下调了每股收益的预期，暗示阿里巴巴健康信息技术可能面临业务逆风。他们还重新确认了营收预期，预计公司将以与更广泛行业相同的速度增长。共识目标价保持在 6.38 港元，最新的估计不足以对他们的目标价产生影响。</p>
</div><p>Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Alibaba Health Information Technology going out to 2029, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>基于这一思路，我们认为业务的长期前景远比明年的盈利更为重要。在 Simply Wall St，我们有阿里巴巴健康信息技术到 2029 年的完整分析师估计，您可以在我们的平台上免费查看。</p>
</div><p>You can also see our analysis of Alibaba Health Information Technology's Board and CEO remuneration and experience, and whether company insiders have been buying stock.</p>
<div class="lb-trans"><p>您还可以查看我们对阿里巴巴健康信息技术董事会和首席执行官薪酬及经验的分析，以及公司内部人士是否在购买股票。</p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

盈利未达预期：阿里健康信息技术有限公司的每股收益低于预期 14%，分析师正在调整他们的预测